Aryl acetic acid and ester derivatives and their uses as antiinflammatory

Details for Australian Patent Application No. 2006322206 (hide)

Owner Novartis AG

Inventors Singh, Harinder Pal; Sandham, David Andrew; Brown, Lyndon Nigel; LeBlanc, Catherine

Agent Davies Collison Cave

Pub. Number AU-B-2006322206

PCT Pub. Number WO2007/065683

Priority 0525144.2 09.12.05 GB

Filing date 7 December 2006

Wipo publication date 14 June 2007

Acceptance publication date 19 August 2010

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

Event Publications

26 June 2008 PCT application entered the National Phase

  PCT publication WO2007/065683 Priority application(s): WO2007/065683

19 August 2010 Application Accepted

  Published as AU-B-2006322206

16 December 2010 Standard Patent Sealed

5 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006322207-Bicyclic heteroyclic compounds as antiinflammatory or antiallergic agents

2006322187-Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors